Efficacy of the class III antiarrhythmic agent azimilide in rodent models of ventricular arrhythmia

Proceedings of the Society for Experimental Biology and Medicine

Volumn 212, Issue 1, 1996, Pages 84-93

  Brooks, Robert R ^a,b   Carpenter, John F ^a   Miller, Kim E ^a   Maynard, Anne E ^a  

^a Proctor and Gamble Pharmaceuticals   (United States)

^b Proctor and Gamble Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ANTIARRHYTHMIC AGENT; AZIMILIDE; DOFETILIDE; OUABAIN; SEMATILIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; DOSE RESPONSE; DRUG EFFICACY; GUINEA PIG; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; RAT;

EID: 0029878868     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.3181/00379727-212-43995     Document Type: Article

References (44)

1. Tatla DS, David BC, Malloy KJ, Moorehead TJ. In vitro electrophysiology of NE-10064, a novel and highly selective class III antiarrhythmic agent. FASEB J 7:A107-615, 1993.
2. Ks is the target for the class III antiarrhythmic drug NE-10064. Circ 88(Suppl):I-231-1233, 1993.
3. + currents in cardiac cells. Biophys J 66:W-Post 33-A326, 1994.
4. Smith MA, Conder ML, Atwal KS, McCullough JR. Effects of clofilium and NE-10064 on IKs, the slow component of the cardiac delayed rectifier. Biophys J 66:A209-Tu-Pos402, 1994.
5. Zhang Z, Boutjdir M, Brooks RR, Chen L, El-Sherif N. Characterization of azimilide effects on ion currents of the repolarization phase. Biophys J 68:A111-M-Pos485, 1995.
6. Fermini B, Jurkiewicz NK, Jow B, Guinosso PJJ, Baskin EP, Lynch JJJ, Salata JJ. Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: Block of delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol 26:259-271, 1995.
7. + currents in human atrial and ventricular myocytes. Circulation 92:1-575-2749, 1995.
8. Gintant GA. Pharmacologic identification of IKs in canine ventricular myocytes: Effects of NE-10064 (azimilide). Circulation 90:1-146-0781, 1994.
9. Mcintosh MA, Tanira M, Pacini D, Kane KA. Comparison of the cardiac electrophysiologic effects of NE-10064 with sotalol and E-4031 and their modification by simulated ischaemia. J Cardiovasc Pharmacol 23:653-657, 1994.
10. Black SC, Butterfield JL, Lucchesi BR. Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug. J Cardiovasc Pharmacol 22:810-818, 1993.
11. Brooks RR, Miller KE, Carpenter JF, Jones SM. Broad sensitivity of rodent arrhythmia models to class I, II, III, and IV antiarrhythmic agents. Proc Soc Exp Biol Med 191:201-208, 1989.
12. Brooks RR, Carpenter JF, Maynard AE, Decker GE. Efficacy of a novel class III antiarrhythmic agent NE-10064 against ischemia/reperfusion arrhythmias in rats. FASEB J 7:A97-557, 1993.
13. Miller KE, Decker GE, Brittain D, Carpenter JF, Brooks RR. The class III antiarrhythmic NE-10064 suppresses ouabain-induced arrhythmias in guinea pigs. Can J Physiol Pharmacol 72(Suppl 1):82-01.1.20, 1994.
14. Lawson JW. Antiarrhythmic activity of some isoquinoline derivatives determined by a rapid screening procedure in the mouse. J Pharmacol Exp Ther 160:22-31, 1968.
15. Manning AS, Coltart DJ, Hearse DJ. Ischemia and reperfusion-induced arrhythmias in the rat. Effects of xanthine oxidase inhibition with allopurinol. Circ Res 55:545-548, 1984.
16. Kane KA, Paratt JR, Williams EM. Reperfusion-induced cardiac arrhythmias in the anesthetized rat and their susceptibility to drugs. Br J Pharmacol 78:122P, 1984.
17. Selye H, Bajusz E, Grasso S, Mendell P. Simple techniques for the surgical occlusion of coronary vessels in the rat. Angiol 11:398-407, 1960.
18. Walker MJA, Curtis MJ, Hearse DJ, et al. The Lambeth Conventions: Guidelines for the study of arrhythmias in ischaemia, infarction, and reperfusion. Cardiovasc Res 22:447-455, 1988.
19. Lubbe WF, Daries PS, Opie LH. Ventricular arrhythmias associated with coronary artery occlusion and reperfusion in the isolated perfused rat heart: A model for assessment of antifibrillatory action of antiarrhythmic agents. Cardiovasc Res 12:212-220, 1978.
20. Johnston KM, MacLeod BA, Walker MJA. Responses to ligation of a coronary artery in conscious rats and the actions of antiarrhythmics. Can J Physiol Pharmacol 61:1340-1353, 1983.
21. Martorana PA, Linz W, Göbel H, Petry P, Schölkens BA. Effects of nicainoprol on reperfusion arrhythmia in the isolated working rat heart and on ischemia and reperfusion arrhythmia and myocardial infarct size in the anesthetized rat. Eur J Pharmacol 143:391-401, 1987.
22. Tanz RD, Russell NJ, Banerian SP, Sharp VH. Ouabain-induced tachyarrhythmias and cell damage in isolated perfused guinea-pig hearts: I. Protection by propranolol. J Mol Cell Cardiol 14:655-671, 1982.
23. Rhee HM, Dutta S, Marks BH. Cardiac Na,K-ATPase activity during positive inotropic and toxic actions of ouabain. Eur J Pharmacol 37:141-153, 1976.
24. Sekiya A, Vaughan Williams EM. The effects of pronethalol, dichloroisoprenaline and disopyramide on the toxicity to the heart of ouabain and anaesthetics. Br J Anaesth 21:462-472, 1963.
25. Bernauer W. Release of adenine nucleotide metabolites by toxic concentrations of cardiac glycosides. Basic Res Cardiol 89:308-321, 1994.
26. Xu J, Hurt CM, Pelleg A. Digoxin-induced ventricular arrhythmias in the guinea pig heart in vivo: Evidence for a role of endogenous catecholamines in the genesis of delayed afterdepolarizations and triggered activity. Heart Vessels 10:119-127, 1995.
27. Kanzik I, Çakici I, Ersoy S, Ark M, Abacioglu N, Zengil H. Effects of cyclooxygenase and lipoxygenase inhibitors on digoxin-induced arrhythmias and haemodynamics in guinea-pigs. Pharmacol Res 26:305-316, 1992.
28. Brandt MA, Maynard AE. NE-10064 exhibits class III antiarrhythmic effects after intravenous or oral administration in conscious dogs. FASEB J 8:A7-38, 1994.
29. Vargaftig B, Coignet JL. A critical evaluation of three methods for the study of adrenergic beta-blocking and anti-arrhythmic agents. Eur J Pharmacol 6:49-55, 1969.
30. Block AJ. Prevention of chloroform-induced ventricular tachycardia in mice as an index of antiarrhythmic activity. Life Sci 28:2623-2629, 1981.
31. Pong SF, Kinney CM, Moorehead TJ. Binding profile of NE-10064, a novel class III antiarrhythmic agent, to rat brain receptors. FASEB J 7:A474-2748, 1993.
32. Miller KE, Carpenter JF, Brooks RR. β-Adrenergic effects of the class III antiarrhythmic agent NE-10064 in the isolated perfused guinea pig heart. FASEB J 7:A108-620, 1993.
33. Winslow E. Methods for the detection and assessment of antiarrhythmic activity. Pharmacol Ther 24:401-433, 1984.
34. + currents in isolated adult rat ventricular myocytes. J Gen Physiol 97:973-1011, 1991.
35. Varro A, Lathrop DA, Hester SB, Nanasi PP, Papp JG. Ionic currents and action potentials in rabbit, rat, and guinea pig ventricular myocytes. Basic Res Cardiol 88:93-102, 1993.
36. Matsubara H, Liman ER, Hess P, Koren G. Pretranslational mechanisms determine the type of potassium channels expressed in the rat skeletal and cardiac muscles. J Biol Chem 266:13324-13328, 1991.
37. + channel gene expression in ventricle of rat heart. Circ Res 75:1006-1013, 1994.
38. Wahler GM, Dollinger SJ, Smith JM, Flemal KL. Time course of postnatal changes in rat heart action potential and in transient outward current is different. Am J Physiol 267:H1157-H1166, 1994.
39. Bril A, Landais L, Gout B. Actions and interactions of E-4031 and tedisamil on reperfusion-induced arrhythmias and QT interval in rat in vivo. Cardiovasc Drugs Ther 7:233-240, 1993.
40. Masuda H, Sperelakis N. Inwardly rectifying potassium current in rat fetal and neonatal ventricular cardiomyocytes. Am J Physiol 265:H1107-H1111, 1993.
41. Rees SA, Curtis MJ. Selective IK blockade as an antiarrhythmic mechanism: Effects of UK66.914 on ischaemia and reperfusion arrhythmias in rat and rabbit hearts. Br J Pharmacol 108:139-145, 1993.
42. Clark RB, Bouchard RA, Saunas Stefanon E, Sanchez Chapula J, Giles WR. Heterogeneity of action potential waveforms and potassium currents in rat ventricle. Cardiovasc Res 27:1795-1799, 1993.
43. Tanz RD, Russell NJ. Mechanism of cardiac glycoside-induced toxicity: Physiology, biochemistry, and electron microscopy. Fed Proc 42:2470-2474, 1983.
44. Apantaku FO, Baumgarten CM, Ten Eick RE. Effect of beta receptor blockade on the initiation and perpetuation of ouabain-induced ventricular tachyarrhythmia. J Pharmacol Exp Ther 193:327-335, 1975.